Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

Maarten Paul Van de Kerkhove, Ernesto Di Florio, Vincenzo Scuderi, Antonio Mancini, Antonello Belli, Adele Bracco, Daniela Scala, Simona Scala, Laura Zeuli, Giuseppe Di Nicuolo, Pietro Amoroso, Fulvio Calise, Robert A F M Chamuleau

Research output: Contribution to journalArticlepeer-review

Abstract

Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.

Original languageEnglish
Pages (from-to)563-568
Number of pages6
JournalCell Transplantation
Volume12
Issue number6
Publication statusPublished - 2003

Keywords

  • Acute liver failure
  • Bioartificial liver
  • Clinical trial
  • Hepatocyte
  • Human
  • Porcine
  • Transplantation

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Fingerprint Dive into the research topics of 'Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver'. Together they form a unique fingerprint.

Cite this